Features | Partner Sites | Information | LinkXpress
Sign In
JIB
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING

Compact Benchtop System Enables Preparative Protein Purification in any Laboratory

By BiotechDaily International staff writers
Posted on 03 Dec 2013
Image: The ÄKTA start protein purification system with the Frac30 fraction collector (Photo courtesy of GE Life Sciences).
Image: The ÄKTA start protein purification system with the Frac30 fraction collector (Photo courtesy of GE Life Sciences).
A compact preparative chromatography instrument that is compatible with prepacked or user prepared columns and can be combined with fraction collectors to generate a complete protein purification system in any biotech or life sciences laboratory is now on the market.

The GE Healthcare (Chalfont St. Giles, United Kingdom) ÄKTA start is designed as a stand-alone system that combines a front-facing flow path with a user-friendly interface. The system is controlled via an intuitive touchscreen, which displays the UV curve and other run data in real-time.

ÄKTA start is compatible with all common purification techniques, including affinity and ion exchange chromatography, desalting, buffer exchange, and gel filtration. The system supports purification of tagged proteins, antibodies, untagged or native proteins, and sample clean-up applications. ÄKTA start can be operated using predefined quick-start protocols, built-in templates, or by creating custom protocols. Prepacked columns are available for common applications.

The ÄKTA start instrument can be augmented with GE Healthcare's Frac30 fraction collector for automatic protein collection, and with user-friendly UNICORN start 1.0 control software, which provides additional evaluation tools and the ability to control ÄKTA start from a computer.

Related Links:

GE Healthcare



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: Synthetic ion transporters can induce apoptosis by facilitating chloride anion transport into cells (Photo courtesy of the University of Texas, Austin).

Experimental Drug Kills Cancer Cells by Interfering with Their Ion Transport Mechanism

An experimental anticancer drug induces cells to enter a molecular pathway leading to apoptosis by skewing their ion transport systems to greatly favor the influx of chloride anions. To promote development... Read more

Therapeutics

view channel
Image: Liver cells regenerated in mice treated with a new drug (right) compared with a control group (center) after partial liver removal. Healthy liver cells are shown at left (Photo courtesy of Marshall et al, 2014, the Journal of Experimental Medicine).

New Drug Triggers Liver Regeneration After Surgery

Investigators have revealed that an innovative complement inhibitor decreases complement-mediated liver cell death, and actually stimulates postsurgery liver regrowth in mice. Liver cancer often results... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.